Back to results
US 2025/0017918 A1Published application
Oral suspensions comprising temozolomide or lenalidomide
AssigneeShorla Pharma Ltd.
InventorsSharon CUNNINGHAM, Orlaith RYAN, Denis DELANEY, Maurice CLANCY, Rod BAKER
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a composition comprising temozolomide or lenalidomide, a medium chain triglyceride such as miglyol, silicon dioxide and a surfactant, wherein the composition optionally comprises an antioxidant and/or a flavoring agent, and wherein the temozolomide composition is a non-aqueous, preservative free suspension. Also provided is a method for treating cancer in a subject, such as a child or a subject suffering dysphagia and/or has difficulty swallowing.
Claims26
A composition comprising:
- about 0.25 to about 100 mg/mL active pharmaceutical ingredient (API);
- about 400 to about 960 mg/mL medium chain triglycerides (MCT);
- about 1 to about 20 mg/mL silicon dioxide;
- and
- about 20 to about 70 mg/mL surfactant;
- wherein the API is temozolomide or lenalidomide,
- wherein the composition is substantially free of water and anti-microbial preservatives, and
- wherein the composition is an oral suspension.
5 more elements
-40. (canceled)
Dependencies are inferred from the claim text.